1
|
Intravital microscopy in the study of the tumor microenvironment: from bench to human application. Oncotarget 2018; 9:20165-20178. [PMID: 29732011 PMCID: PMC5929454 DOI: 10.18632/oncotarget.24957] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Accepted: 03/15/2018] [Indexed: 12/31/2022] Open
Abstract
Intravital microscopy (IVM) is a dynamic imaging modality that allows for the real time observation of biologic processes in vivo, including angiogenesis and immune cell interactions. In the setting of preclinical cancer models, IVM has facilitated an understanding of the tumor associated vasculature and the role of effector immune cells in the tumor microenvironment. Novel approaches to apply IVM to human malignancies have thus far focused on cancer diagnosis and tumor vessel characterization, but have the potential to provide advances in the field of personalized medicine by identifying individual patients who may respond to systemically delivered chemotherapeutic drugs or immunotherapeutic agents. In this review, we highlight the role that IVM has had in investigating tumor vasculature and the tumor microenvironment in preclinical studies and discuss its current and future applications to directly observe human tumors.
Collapse
|
2
|
Wei L, Wang L, Liu Z, Wang M, Lu W, Zhao D, Yang B, Kong X, Ding Y, Wang Z. Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed. Oncotarget 2017; 8:57898-57904. [PMID: 28915721 PMCID: PMC5593693 DOI: 10.18632/oncotarget.19649] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 07/18/2017] [Indexed: 12/11/2022] Open
Abstract
High recurrence rates and poor survival rates for late stage/advanced temporal bone squamous cell carcinoma with the standard treatments continues to be a significant challenge to otolaryngologists. Targeted therapy for temporal bone squamous cell carcinoma after relapse has not been reported. Here we present a 58-year-old man who was diagnosed with recurrent temporal bone squamous cell carcinoma and treated with a regimen developed using whole exome sequencing. Somatic mutations in genes encoding catenin beta 1 and vascular endothelial growth factor receptor 2 were identified in the patient’s tumor sample compared to the normal tissue. The patient was then treated with Bevacizumab in combination with pemetrexed. After two weeks of treatment, tumor volume was reduced by 95% measured by MRI, and the Visual Analogue Scale headache scores went down from 10/10 to 2/10. Our results reveal novel gene mutations of temporal bone squamous cell carcinoma and demonstrate, for the first time, an effective targeted therapy for temporal bone squamous cell carcinoma. The successful treatment regimen of bevacizumab and pemetrexed may provide a new treatment option for treating recurrent temporal bone squamous cell carcinoma that fails to respond to conventional tumor resection, radiotherapy, and/or chemotherapy.
Collapse
Affiliation(s)
- Lai Wei
- Department of Otolaryngology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
| | - Lizhi Wang
- Department of Otolaryngology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
| | - Ziye Liu
- Department of Otolaryngology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
| | - Meiyi Wang
- Department of Otolaryngology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
| | - Weili Lu
- Department of Otolaryngology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
| | - Dewei Zhao
- The Institute for Translational Medicine, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
| | - Bin Yang
- The Institute for Translational Medicine, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
| | - Xuejun Kong
- Department of Pediatrics, Children's Hospital of Boston, Harvard Medical School, Boston, MA, USA
| | - Yan Ding
- The Institute for Translational Medicine, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.,Department of Pediatrics, Children's Hospital of Boston, Harvard Medical School, Boston, MA, USA.,Program for Autism Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Zhiqiang Wang
- Department of Otolaryngology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
| |
Collapse
|
3
|
Misawa Y, Misawa K, Kanazawa T, Uehara T, Endo S, Mochizuki D, Yamatodani T, Carey TE, Mineta H. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer. Cancer 2013; 120:205-13. [DOI: 10.1002/cncr.28411] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Revised: 09/07/2013] [Accepted: 09/11/2013] [Indexed: 01/28/2023]
Affiliation(s)
- Yuki Misawa
- Department of Otolaryngology/Head and Neck Surgery; Hamamatsu University School of Medicine; Shizuoka Japan
| | - Kiyoshi Misawa
- Department of Otolaryngology/Head and Neck Surgery; Hamamatsu University School of Medicine; Shizuoka Japan
| | - Takeharu Kanazawa
- Department of Otolaryngology/Head and Neck Surgery; Jichi Medical University; Tochigi Japan
| | - Takayuki Uehara
- Department of Otolaryngology/Head and Neck Surgery; Jichi Medical University; Tochigi Japan
| | - Shori Endo
- Department of Otolaryngology/Head and Neck Surgery; Hamamatsu University School of Medicine; Shizuoka Japan
| | - Daiki Mochizuki
- Department of Otolaryngology/Head and Neck Surgery; Hamamatsu University School of Medicine; Shizuoka Japan
| | - Takashi Yamatodani
- Department of Otolaryngology/Head and Neck Surgery; Hamamatsu University School of Medicine; Shizuoka Japan
| | - Thomas E. Carey
- Laboratory of Head and Neck Cancer Biology, Department of Otolaryngology/Head and Neck Surgery; University of Michigan; Ann Arbor Michigan
| | - Hiroyuki Mineta
- Department of Otolaryngology/Head and Neck Surgery; Hamamatsu University School of Medicine; Shizuoka Japan
| |
Collapse
|